Analysts Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) to Announce -$0.20 EPS

Equities analysts expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report ($0.20) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Ironwood Pharmaceuticals posted earnings of ($0.28) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The firm is expected to announce its next quarterly earnings report on Thursday, August 2nd.

On average, analysts expect that Ironwood Pharmaceuticals will report full year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.67). For the next fiscal year, analysts expect that the business will post earnings of ($0.05) per share, with EPS estimates ranging from ($0.42) to $0.41. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Tuesday, May 1st. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.06). Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The firm had revenue of $69.16 million during the quarter, compared to analysts’ expectations of $78.65 million. During the same quarter in the prior year, the firm earned ($0.33) EPS. The firm’s revenue was up 32.6% compared to the same quarter last year.

A number of research analysts recently issued reports on IRWD shares. Wells Fargo & Co set a $22.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 30th. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 27th. Berenberg Bank assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Thursday, April 19th. They set a “buy” rating and a $25.00 price objective for the company. Mizuho upgraded shares of Ironwood Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $16.00 to $24.00 in a research report on Wednesday, May 2nd. Finally, ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $19.44.

In other news, Director Julie Mchugh sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 5th. The shares were sold at an average price of $17.62, for a total transaction of $26,430.00. Following the completion of the sale, the director now owns 92,631 shares in the company, valued at approximately $1,632,158.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.63% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in IRWD. BVF Inc. IL purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at $85,519,000. OppenheimerFunds Inc. purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at $39,903,000. Sarissa Capital Management LP purchased a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $24,733,000. Senzar Asset Management LLC raised its position in Ironwood Pharmaceuticals by 185.8% in the 4th quarter. Senzar Asset Management LLC now owns 1,448,800 shares of the biotechnology company’s stock valued at $21,718,000 after purchasing an additional 941,800 shares during the last quarter. Finally, Park West Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $9,203,000.

Ironwood Pharmaceuticals stock traded up $0.17 during trading on Friday, reaching $19.12. The stock had a trading volume of 1,145,532 shares, compared to its average volume of 1,345,551. Ironwood Pharmaceuticals has a 52-week low of $12.89 and a 52-week high of $19.79. The company has a quick ratio of 4.40, a current ratio of 4.42 and a debt-to-equity ratio of -21.52. The company has a market capitalization of $2.88 billion, a P/E ratio of -20.56 and a beta of 1.11.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply